周一盘前交易中，新冠疫苗制造商诺瓦瓦克斯医药（NVAX）股价大跌11.57%，引发市场广泛关注。这一跌势似乎与美国食品和药物管理局（FDA）最高疫苗官员彼得·马克斯（Peter Marks）被迫离职的消息有关。
据《华尔街日报》等媒体报道，马克斯被迫在辞职和被解雇之间做出选择，其辞职将于4月5日生效。马克斯在特朗普总统第一任期内对开发新冠疫苗发挥了关键作用。这一人事变动引发了投资者对疫苗行业前景的担忧，导致包括诺瓦瓦克斯在内的多家疫苗制造商股价下跌。
值得注意的是，自特朗普再次当选并任命著名疫苗怀疑论者小罗伯特·肯尼迪（Robert F. Kennedy Jr）领导美国最高卫生机构——卫生与公众服务部以来，疫苗股票一直承受压力。这一最新发展进一步加剧了市场对疫苗行业未来政策环境的担忧，可能是导致诺瓦瓦克斯医药等公司股价大幅下跌的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.